A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase

Recruiting now

Conditions studied: Hematopoietic and Lymphatic System Neoplasm, Acute Lymphobkastic Leukemia

In brief

This study evaluates the incidence of symptomatic hyperammonemia (high ammonia levels) in patients being treated with recombinant Erwinia asparaginase.

Key facts

Study ID

NCT06600659

Run by

Mayo Clinic

People needed

10

Starts

2023-11-02

Expected to finish

2026-12-01

Last updated by the study team

2026-02-06

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Followed by pediatric hematology/oncology
• Receiving recombinant Erwinia asparaginase for treatment of malignancy

You may not qualify if…

• Patients < 1 year of age
• Patients who have previously received recombinant Erwinia asparaginase within the past two weeks

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.